Table 1.
Characteristics of patients from the two therapy groups (results presented as mean ± SD).
| AMSs (n = 23) | Anti-TNF (n = 18) | p value | |
|---|---|---|---|
| Age (years) | 38.7 ± 12.5 | 33.6 ± 8.8 | ns |
| Gender | 16 M/7 F | 9 M/9 F | ns |
| BMI (kg/m2) | 23.1 ± 1.7 | 23.3 ± 3.4 | ns |
| Fasting glucose (mg/dl) | 93.4 ± 14.9 | 88 ± 10.7 | ns |
| Insulin (μIU/ml) | 12.1 ± 6.6 | 10.9 ± 7.9 | ns |
| C-peptide (ng/ml) | 2.2 ± 1.4 | 1.9 ± 0.9 | ns |
| HbA1c (%) | 5.3 ± 0.4 | 5.2 ± 0.3 | ns |
| Cholesterol (mg/dl) | 162.8 ± 34.3 | 168.6 ± 32.7 | ns |
| HDL (mg/dl) | 53.8 ± 20.3 | 57.5 ± 15.7 | ns |
| LDL (mg/dl) | 90.7 ± 24.4 | 95.8 ± 28.7 | ns |
| Triglycerides (mg/dl) | 90.8 ± 61.3 | 75.8 ± 37.6 | ns |
| CRP (mg/l) | 4.9 ± 6.1 | 3 ± 5.4 | ns |
| HOMA-IR | 3.1 ± 1.9 | 2.77 ± 2 | ns |
AMSs: aminosalicylates; BMI: body mass index; CRP: C-reactive protein; HDL: high-density lipoprotein; HOMA-IR: homeostatic model assessment insulin resistance; LDL: low-density lipoprotein; TNFα: tumor necrosis factor alpha.